MX2018001213A - Nuevos metodos para inducir una respuesta inmunitaria. - Google Patents
Nuevos metodos para inducir una respuesta inmunitaria.Info
- Publication number
- MX2018001213A MX2018001213A MX2018001213A MX2018001213A MX2018001213A MX 2018001213 A MX2018001213 A MX 2018001213A MX 2018001213 A MX2018001213 A MX 2018001213A MX 2018001213 A MX2018001213 A MX 2018001213A MX 2018001213 A MX2018001213 A MX 2018001213A
- Authority
- MX
- Mexico
- Prior art keywords
- inducing
- immune response
- administration
- related antigen
- novel methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para inducir una respuesta inmunitaria, en particular métodos para inducir una respuesta inmunitaria en contra de infecciones micobacterianas o enfermedad que comprende (i) al menos una administración de un antígeno relacionado con el polipéptido Rv1196 y al menos una administración de un adenovirus que codifica un antígeno relacionado con Rv0125. También se proporcionan composiciones asociadas, constructos adenovirales y secuencias de polinucleótidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1513176.6A GB201513176D0 (en) | 2015-07-27 | 2015-07-27 | Novel methods for inducing an immune response |
PCT/EP2016/067622 WO2017017050A1 (en) | 2015-07-27 | 2016-07-25 | Novel methods for inducing an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001213A true MX2018001213A (es) | 2018-04-13 |
Family
ID=54106649
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001215A MX2018001215A (es) | 2015-07-27 | 2016-07-25 | Adenovirus novedoso. |
MX2018001213A MX2018001213A (es) | 2015-07-27 | 2016-07-25 | Nuevos metodos para inducir una respuesta inmunitaria. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001215A MX2018001215A (es) | 2015-07-27 | 2016-07-25 | Adenovirus novedoso. |
Country Status (15)
Country | Link |
---|---|
US (4) | US11110159B2 (es) |
EP (2) | EP3328421A1 (es) |
JP (2) | JP2018524393A (es) |
KR (1) | KR20180034589A (es) |
CN (2) | CN108367061A (es) |
AR (1) | AR105470A1 (es) |
AU (1) | AU2016301029B2 (es) |
BE (2) | BE1023915B1 (es) |
BR (2) | BR112018001683A2 (es) |
CA (2) | CA2993277A1 (es) |
EA (1) | EA201890355A1 (es) |
GB (1) | GB201513176D0 (es) |
IL (1) | IL257071A (es) |
MX (2) | MX2018001215A (es) |
WO (2) | WO2017017050A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
DK3436591T3 (da) * | 2016-03-31 | 2023-03-20 | The European Molecular Biology Laboratory | Adenovirale coat-protein-afledte transportvehikler |
JP2019536468A (ja) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍を標的にする合成アデノウイルスおよびその使用 |
BR112020007413A2 (pt) * | 2017-10-16 | 2020-12-08 | Glaxosmithkline Biologicals S.A. | Vetores adenovirais com dois cassetes de expressão |
CN111527213A (zh) | 2017-10-16 | 2020-08-11 | 葛兰素史密丝克莱恩生物有限公司 | 具有两个编码rsv抗原蛋白或片段的表达盒的腺病毒载体 |
JP2020537525A (ja) * | 2017-10-16 | 2020-12-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 複製能力のあるアデノウイルスベクター |
MX2020003389A (es) * | 2017-10-16 | 2022-08-04 | Glaxosmithkline Biologicals Sa | Promotor mejorado. |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
MX2020013553A (es) * | 2018-06-12 | 2021-02-26 | Glaxosmithkline Biologicals Sa | Polinucleotidos y polipeptidos de adenovirus. |
EP3737411A4 (en) | 2018-08-10 | 2022-01-05 | NantBio, Inc. | CELLULAR ADJUVANTS FOR VIRAL INFECTION |
TW202043256A (zh) * | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | ***新抗原及其用途 |
CN110283766B (zh) * | 2019-05-13 | 2020-12-18 | 华中科技大学 | 一种重组卡介苗及其构建与应用 |
CN110606875A (zh) * | 2019-09-20 | 2019-12-24 | 中国农业科学院兰州兽医研究所 | 一种用于制备***疫苗的分子内佐剂及其应用和***疫苗 |
AU2020357740A1 (en) * | 2019-09-30 | 2022-04-28 | Eli Lilly And Company | Adeno-associated virus (AAV) systems for treatment of genetic hearing loss |
CN113088530A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法 |
CN113088538A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法 |
CN114438128A (zh) * | 2020-10-30 | 2022-05-06 | 上海市公共卫生临床中心 | 一种增强型溶瘤腺病毒及其应用 |
CA3226978A1 (en) * | 2021-08-31 | 2023-03-09 | Vir Biotechnology, Inc. | Tuberculosis vaccines |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69637879D1 (de) | 1995-09-01 | 2009-04-30 | Corixa Corp | Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose |
US6350456B1 (en) | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
PT1542732E (pt) * | 2000-06-20 | 2009-11-06 | Corixa Corp | Proteínas de fusão de mycobacterium tuberculosis |
US7026465B2 (en) * | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
CA2993042A1 (en) * | 2004-01-23 | 2005-08-04 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
ES2442225T3 (es) * | 2004-04-28 | 2014-02-10 | The Trustees Of The University Of Pennsylvania | Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1 |
JP5164830B2 (ja) * | 2005-04-29 | 2013-03-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 結核菌感染の予防または治療のための新規方法 |
WO2006133911A2 (en) | 2005-06-17 | 2006-12-21 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hepatitis c virus nucleic acid vaccine |
KR101532062B1 (ko) | 2007-03-02 | 2015-06-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 신규한 방법 및 조성물 |
MX2010005860A (es) | 2007-11-28 | 2010-06-22 | Univ Pennsylvania | Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos. |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
KR101763093B1 (ko) * | 2009-02-02 | 2017-07-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도 |
GB0918154D0 (en) | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
MY156697A (en) * | 2010-01-27 | 2016-03-15 | Glaxosmithkline Biolog Sa | Modified tuberculosis antigens |
EP3466440A1 (en) * | 2010-04-16 | 2019-04-10 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
EP2651437B1 (en) * | 2010-12-14 | 2016-02-10 | GlaxoSmithKline Biologicals S.A. | Mycobacterium antigenic composition |
WO2013123579A1 (en) * | 2012-02-24 | 2013-08-29 | Mcmaster University | Adenovirus-based tuberculosis vaccine and its use |
CN108025058B (zh) | 2015-06-12 | 2022-12-16 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
-
2015
- 2015-07-27 GB GBGB1513176.6A patent/GB201513176D0/en not_active Ceased
-
2016
- 2016-07-25 KR KR1020187005661A patent/KR20180034589A/ko unknown
- 2016-07-25 EP EP16745090.7A patent/EP3328421A1/en active Pending
- 2016-07-25 WO PCT/EP2016/067622 patent/WO2017017050A1/en active Application Filing
- 2016-07-25 BE BE20165611A patent/BE1023915B1/fr not_active IP Right Cessation
- 2016-07-25 US US15/747,671 patent/US11110159B2/en active Active
- 2016-07-25 MX MX2018001215A patent/MX2018001215A/es unknown
- 2016-07-25 AU AU2016301029A patent/AU2016301029B2/en not_active Ceased
- 2016-07-25 EP EP16741946.4A patent/EP3328420A1/en active Pending
- 2016-07-25 CA CA2993277A patent/CA2993277A1/en not_active Abandoned
- 2016-07-25 BR BR112018001683A patent/BR112018001683A2/pt not_active Application Discontinuation
- 2016-07-25 EA EA201890355A patent/EA201890355A1/ru unknown
- 2016-07-25 WO PCT/EP2016/067621 patent/WO2017017049A1/en active Application Filing
- 2016-07-25 MX MX2018001213A patent/MX2018001213A/es unknown
- 2016-07-25 CA CA2993371A patent/CA2993371A1/en not_active Abandoned
- 2016-07-25 US US15/747,545 patent/US20180216081A1/en not_active Abandoned
- 2016-07-25 JP JP2018503747A patent/JP2018524393A/ja active Pending
- 2016-07-25 BR BR112018001572A patent/BR112018001572A2/pt not_active Application Discontinuation
- 2016-07-25 AR ARP160102263A patent/AR105470A1/es unknown
- 2016-07-25 JP JP2018504131A patent/JP2018521666A/ja active Pending
- 2016-07-25 CN CN201680043249.8A patent/CN108367061A/zh active Pending
- 2016-07-25 CN CN201680056024.6A patent/CN108135991A/zh active Pending
- 2016-07-25 BE BE20165610A patent/BE1023916A9/fr not_active IP Right Cessation
-
2018
- 2018-01-22 IL IL257071A patent/IL257071A/en unknown
-
2020
- 2020-08-06 US US16/986,413 patent/US20210060150A1/en active Pending
-
2021
- 2021-08-09 US US17/397,379 patent/US20210386846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA201890355A1 (ru) | 2018-08-31 |
BE1023916A1 (fr) | 2017-09-12 |
KR20180034589A (ko) | 2018-04-04 |
GB201513176D0 (en) | 2015-09-09 |
BE1023915A9 (fr) | 2018-01-24 |
AR105470A1 (es) | 2017-10-04 |
BE1023916B1 (fr) | 2018-01-22 |
CA2993277A1 (en) | 2017-02-02 |
IL257071A (en) | 2018-03-29 |
MX2018001215A (es) | 2018-04-13 |
US20210060150A1 (en) | 2021-03-04 |
CN108367061A (zh) | 2018-08-03 |
US20180250375A1 (en) | 2018-09-06 |
BE1023916A9 (fr) | 2018-02-12 |
EP3328420A1 (en) | 2018-06-06 |
BE1023915A1 (fr) | 2017-09-12 |
CN108135991A (zh) | 2018-06-08 |
US20210386846A1 (en) | 2021-12-16 |
WO2017017050A1 (en) | 2017-02-02 |
BE1023915B1 (fr) | 2018-01-31 |
JP2018524393A (ja) | 2018-08-30 |
EP3328421A1 (en) | 2018-06-06 |
JP2018521666A (ja) | 2018-08-09 |
CA2993371A1 (en) | 2017-02-02 |
BR112018001683A2 (pt) | 2018-09-18 |
WO2017017049A1 (en) | 2017-02-02 |
AU2016301029B2 (en) | 2019-08-22 |
BR112018001572A2 (pt) | 2018-11-06 |
US11110159B2 (en) | 2021-09-07 |
AU2016301029A1 (en) | 2018-02-01 |
US20180216081A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
EA202091004A1 (ru) | Аденовирус и пути его применения | |
EA202091074A1 (ru) | Аденовирус и его применения | |
MY192226A (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
MX2017009538A (es) | Antigenos de citomegalovirus y su uso. | |
TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
MY182667A (en) | Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein | |
JO3772B1 (ar) | صيغة جسم مضاد لـ cgrp | |
WO2016019134A8 (en) | Flagellin-based agents and uses including effective vaccination | |
PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
EA201891460A1 (ru) | Композиция дендритных клеток | |
PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
MX2016012479A (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
BR112017002183A2 (pt) | conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero | |
EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
WO2015095249A8 (en) | Single chain il-12 nucleic acids, polypeptids, and uses thereof | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
MY191539A (en) | Streptococcal vaccine | |
EA201591798A1 (ru) | Композиции и способы усиления иммунного ответа на кишечные патогены | |
MX2020003093A (es) | Anticuerpos anti-cd19 novedosos. | |
ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |